Brought to you by 
Seven and Eight Biopharmaceuticals to combine BDB001 with Roche’s Tecentriq
26 Oct 2021
Executive Summary
Seven and Eight Biopharmaceuticals Inc. and Roche agreed to trial a combination of the former’s BDB001 and latter’s Tecentriq (atezolizumab) in solid tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seven and Eight Biopharmaceuticals to combine BDB001 with Roche’s Tecentriq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice